The role of red blood cell characteristics and viscosity in sickle cell retinopathy and maculopathy
- PMID: 40296702
- PMCID: PMC12166350
- DOI: 10.1111/bjh.20124
The role of red blood cell characteristics and viscosity in sickle cell retinopathy and maculopathy
Abstract
Sickle cell disease (SCD), encompassing genotypes such as HbSS and HbSC, causes chronic haemolysis and microvascular occlusion, leading to organ damage. The retina is particularly vulnerable, often resulting in sickle cell retinopathy (SCR) or sickle cell maculopathy (SCM). The precise underlying mechanisms are unclear, though various factors are suggested to contribute. This study explored the role of whole blood viscosity and red blood cell (RBC) deformability in SCR and SCM. Adult HbSS (n = 34) and HbSC patients (n = 34) were offered an ophthalmic examination to determine SCR stage. A venous ethylenediaminetetraacetic acid (EDTA) sample was collected from each participant. Whole blood viscosity was measured using a Brookfield viscometer and RBC deformability was assessed using the Oxygenscan feature of the Laser Optical Rotational Red Cell Analyser as a function of the (varying) partial oxygen pressure. HbSC patients with proliferative sickle cell retinopathy (PSCR) had a lower delta elongation index (p = 0.012) and point of sickling (p = 0.002) than those without PSCR, suggesting that RBC sickling might not play a central role in the pathogenesis of PSCR in HbSC patients. Despite hyperviscosity being a commonly proposed mechanism, no associations were found between blood viscosity, SCR and SCM. These results point to alternative mechanisms contributing to SCR and SCM, highlighting the complexity and need for further research to fully understand the underlying factors.
Keywords: erythrocyte deformability; sickle cell disease; sickle cell maculopathy; sickle cell retinopathy; viscosity.
© 2025 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Conflict of interest statement
RPB has received research grants from Stichting Pupil (Pupil Foundation, the Netherlands), Stichting UitZicht (UitZicht Foundation, the Netherlands), Het Sikkelcelfonds (the Netherlands), the Maarten Kappelle Stichting (the Netherlands) and the Rotterdamse Stichting Blindenbelangen (the Netherlands). ROS has received research grants from Novartis and Boeringer‐Ingelheim and participated in advisory board meetings of Apellis, Boeringer‐Ingelheim and Ciana Therapeutics. EN has received a research grant from Novartis and participated in the advisory board and speakers' bureau of Novartis. BJB has received research grants from Sanquin, Novartis, GBT/Pfizer and BMS/Celgene; participated in advisory board meetings of BMS/Celgene, Novo Nordisk and GBT/Pfizer; and received honoraria from Sanofi and Novo Nordisk. RMHD and IK have no conflicts of interest to declare.
Figures


References
-
- Duan XJ, Lanzkron S, Linz MO, Ewing C, Wang J, Scott AW. Clinical and ophthalmic factors associated with the severity of sickle cell retinopathy. Am J Ophthalmol. 2019;197:105–113. - PubMed
-
- Andrawes NG, Ismail EA, Roshdy MM, Ebeid FSE, Eissa DS, Ibrahim AM. Angiopoietin‐2 as a marker of retinopathy in children and adolescents with sickle cell disease: relation to subclinical atherosclerosis. J Pediatr Hematol Oncol. 2019;41(5):361–370. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical